340 related articles for article (PubMed ID: 27000800)
21. Timing of new black box warnings and withdrawals for prescription medications.
Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
[TBL] [Abstract][Full Text] [Related]
22. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
[TBL] [Abstract][Full Text] [Related]
23. Trends in Incident Varenicline Prescribing Among Veterans Following the US Food and Drug Administration Drug Safety Warnings.
Gerlach LB; Van T; Kim HM; Chang MM; Bohnert KM; Zivin K
J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936245
[No Abstract] [Full Text] [Related]
24. Information shocks and pharmaceutical firms' marketing efforts: Evidence from the Chantix black box warning removal.
Lawler EC; Skira MM
J Health Econ; 2022 Jan; 81():102557. PubMed ID: 34896791
[TBL] [Abstract][Full Text] [Related]
25. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
Office of Health & Constituent Affairs U.S. Food and Drug Administration
Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
[No Abstract] [Full Text] [Related]
26. Black-box warnings could be removed from varenicline.
Mohammadi D
Lancet Respir Med; 2016 Nov; 4(11):861. PubMed ID: 27742352
[No Abstract] [Full Text] [Related]
27. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
28. Summaries of safety labeling changes approved by FDA-Boxed Warnings Highlights October-December 2014.
Rubio T
Am J Health Syst Pharm; 2015 Mar; 72(5):343. PubMed ID: 25694404
[No Abstract] [Full Text] [Related]
29. Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence.
Kloet MA; Lohr BR; Smithburger PL; Seybert AL; Kane-Gill SL
J Patient Saf; 2017 Mar; 13(1):25-30. PubMed ID: 24647270
[TBL] [Abstract][Full Text] [Related]
30. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2017.
Office of Health and Constituent Affairs, U.S. Food and Drug Administration
Am J Health Syst Pharm; 2017 Jun; 74(11):e292-e294. PubMed ID: 28546306
[No Abstract] [Full Text] [Related]
31. Semantic processing to identify adverse drug event information from black box warnings.
Culbertson A; Fiszman M; Shin D; Rindflesch TC
AMIA Annu Symp Proc; 2014; 2014():442-8. PubMed ID: 25954348
[TBL] [Abstract][Full Text] [Related]
32. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.
Am J Health Syst Pharm; 2019 Jun; 76(13):e8-e9. PubMed ID: 31361888
[No Abstract] [Full Text] [Related]
33. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
34. Black box warnings: what do they mean to pharmacists and patients.
Martin CM; Borgelt L
Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
[TBL] [Abstract][Full Text] [Related]
35. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
[TBL] [Abstract][Full Text] [Related]
36. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
[TBL] [Abstract][Full Text] [Related]
37. Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
[TBL] [Abstract][Full Text] [Related]
38. FDA Boxed Warning for Immediate-Release Opioids.
Food And Drug Administration Public Health Service U S Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
[TBL] [Abstract][Full Text] [Related]
39. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, January-March 2024.
Am J Health Syst Pharm; 2024 Jun; 81(13):e330-e334. PubMed ID: 38801728
[No Abstract] [Full Text] [Related]
40. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights April-June 2015.
Am J Health Syst Pharm; 2015 Sep; 72(17):1430. PubMed ID: 26294231
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
